InsiderTrades.com logo
Caryn Parlavecchio net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Caryn Parlavecchio Biography and Net Worth

Insider of Scholar Rock

Caryn Parlavecchio joined Scholar Rock in August 2021 as Chief Human Resources Officer, overseeing talent management, diversity and inclusion initiatives, and developing and implementing human resources strategies. Previously, she served as Vice President and Chief Human Resources Officer at Holy Name Medical, where she was a member of the executive team, HR committee, finance committee, and compensation and benefits committees. From 2001 to 2020, Caryn held various human resource leadership positions at Novartis Pharmaceuticals, including Vice President and Global HR Head, Oncology & Pharma Development, Vice President and Country HR Head, and Vice President, Human Resources Services, North America. She received a M.A. in Counseling Psychology and a B.A in English, both from Seton Hall University.

What is Caryn Parlavecchio's net worth?

The estimated net worth of Caryn Parlavecchio is at least $4.95 million as of August 16th, 2024. Mr. Parlavecchio owns 151,988 shares of Scholar Rock stock worth more than $4,945,690 as of April 3rd. This net worth evaluation does not reflect any other investments that Mr. Parlavecchio may own. Learn More about Caryn Parlavecchio's net worth.

How old is Caryn Parlavecchio?

Mr. Parlavecchio is currently 52 years old. There are 5 older executives and no younger executives at Scholar Rock. The oldest executive at Scholar Rock is Dr. Jay Thomas Backstrom M.D., M.P.H., President, CEO & Director, who is 69 years old. Learn More on Caryn Parlavecchio's age.

How do I contact Caryn Parlavecchio?

The corporate mailing address for Mr. Parlavecchio and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at chu@scholarrock.com. Learn More on Caryn Parlavecchio's contact information.

Has Caryn Parlavecchio been buying or selling shares of Scholar Rock?

Caryn Parlavecchio has not been actively trading shares of Scholar Rock in the last ninety days. Most recently, Caryn Parlavecchio sold 1,451 shares of the business's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $9.33, for a transaction totalling $13,537.83. Following the completion of the sale, the insider now directly owns 151,988 shares of the company's stock, valued at $1,418,048.04. Learn More on Caryn Parlavecchio's trading history.

Who are Scholar Rock's active insiders?

Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Jeffrey Flier (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), and Tracey Sacco (Chief Commercial Officer). Learn More on Scholar Rock's active insiders.

Are insiders buying or selling shares of Scholar Rock?

In the last year, insiders at the sold shares 20 times. They sold a total of 2,141,013 shares worth more than $67,818,845.02. The most recent insider tranaction occured on March, 24th when insider Tracey Sacco sold 6,500 shares worth more than $215,020.00. Insiders at Scholar Rock own 19.2% of the company. Learn More about insider trades at Scholar Rock.

Information on this page was last updated on 3/24/2025.

Caryn Parlavecchio Insider Trading History at Scholar Rock

See Full Table

Caryn Parlavecchio Buying and Selling Activity at Scholar Rock

This chart shows Caryn Parlavecchio's buying and selling at Scholar Rock by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40k-$20k$0$20k$40kTotal Insider BuyingTotal Insider Selling

Scholar Rock Company Overview

Scholar Rock logo
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $32.54
Low: $29.85
High: $32.55

50 Day Range

MA: $36.94
Low: $30.06
High: $45.40

2 Week Range

Now: $32.54
Low: $6.76
High: $46.98

Volume

1,460,565 shs

Average Volume

1,176,557 shs

Market Capitalization

$3.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59